Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (11-20 of 386) with videos related to

Pageof 39
Sort By:
Blood|March 3, 2018
R-spondin(g) to syndecan-1 in myelomaSteven Grant
The Journal of Clinical Investigation|August 30, 2008
Cotargeting survival signaling pathways in cancerSteven Grant
Cell Cycle (Georgetown, Tex.)|September 23, 2009
Selectively killing transformed cells through proteasome inhibitionSteven Grant
Best Practice & Research. Clinical Haematology|December 2, 2008
Is the focus moving toward a combination of targeted drugs?Steven Grant
Blood|February 4, 2021
Targeting cereblon in AMLSteven Grant
British Journal of Nursing (Mark Allen Publishing)|June 13, 2018
Limitations of track and trigger systems and the National Early Warning Score. Part 1: areas of contentionSteven Grant
Frontiers of Health Services Management|April 7, 2010
Diversity in healthcare: driven by leadershipSteven Grant
The Journal of Clinical Investigation|August 14, 2012
FAM83A and FAM83B: candidate oncogenes and TKI resistance mediatorsSteven Grant
Blood|May 30, 2015
ATRA and ATO team up against NPM1Steven Grant
Oncotarget|April 29, 2011
Enhancing proteotoxic stress as an anticancer strategySteven Grant
Pageof 39

Showing results (11-20 of 386) with videos related to

Sort By:
Pageof 39
Blood|March 3, 2018
R-spondin(g) to syndecan-1 in myelomaSteven Grant
The Journal of Clinical Investigation|August 30, 2008
Cotargeting survival signaling pathways in cancerSteven Grant
Cell Cycle (Georgetown, Tex.)|September 23, 2009
Selectively killing transformed cells through proteasome inhibitionSteven Grant
Best Practice & Research. Clinical Haematology|December 2, 2008
Is the focus moving toward a combination of targeted drugs?Steven Grant
Blood|February 4, 2021
Targeting cereblon in AMLSteven Grant
British Journal of Nursing (Mark Allen Publishing)|June 13, 2018
Limitations of track and trigger systems and the National Early Warning Score. Part 1: areas of contentionSteven Grant
Frontiers of Health Services Management|April 7, 2010
Diversity in healthcare: driven by leadershipSteven Grant
The Journal of Clinical Investigation|August 14, 2012
FAM83A and FAM83B: candidate oncogenes and TKI resistance mediatorsSteven Grant
Blood|May 30, 2015
ATRA and ATO team up against NPM1Steven Grant
Oncotarget|April 29, 2011
Enhancing proteotoxic stress as an anticancer strategySteven Grant
Pageof 39